PERJETA (Pertuzumab)

PERJETA (Pertuzumab)

Regular price
$4,729.99 USD
Sale price
$4,729.99 USD
Regular price
Sold out
Unit price
Shipping calculated at checkout.

prescription refrigerated

What is this medication?

PERJETA (Pertuzumab)
HER2/neu receptor antagonist

PERJETA (Pertuzumab) is a HER2/neu receptor antagonist indicated in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.

Exposure to PERJETA (Pertuzumab) can result in embryo-fetal death and birth defects. Studies in animals have resulted in oligohydramnios, delayed renal development, and death. Advise patients of these risks and the need for effective contraception.

How does this medication work? 

PERJETA (Pertuzumab) is a recombinant humanized monoclonal antibody that targets human epidermal growth factor receptor 2 protein (HER2) and, thereby, blocks ligand-initiated intracellular signaling through two major signal pathways, mitogen-activated protein (MAP) kinase and phosphoinositide 3-kinase 300 (PI3K). Inhibition of these signaling pathways can result in cell growth arrest and apoptosis.

How should I take this medication? 

IV: Initial dose is 840 mg administered as a 60-minute intravenous infusion, followed every 3 weeks thereafter by 420 mg administered as a 30 to 60 minute intravenous infusion.

Note: Do not administer as an intravenous push or bolus.

What should I watch for while using this medication? 

Before starting PERJETA (Pertuzumab) make sure your physician is aware of any allergies or medications you currently take. Pertuzumab has been shown to cause left ventricular dysfunction.  Monitor cardiac function, in particular left ventricular ejection fraction for signs of heart failure.  Monitor for signs and symptoms of infusion-associated reactions.  

What if I miss a dose?

For delayed or missed doses, if the time between two sequential infusions is less than 6 weeks, the 420 mg dose of PERJETA (Pertuzumab) should be administered. Do not wait until the next planned dose. If the time between two sequential infusions is 6 weeks or more, the initial dose of 840 mg Pertuzumab should be re-administered as a 60-minute intravenous infusion followed every 3 weeks thereafter by a dose of 420 mg administered as an intravenous infusion over 30 to 60 minutes.

How should I store this medication?

Store vials refrigerated at 2°C to 8°C (36°F to 46°F) until time of use. Protect from light. Do not freeze. Do not shake. Solutions diluted for infusion should be used immediately. If not used immediately, diluted solutions may be stored at 2°C to 8°C for up to 24 hours.

What are the possible side effects of using this medication?

Diarrhea, alopecia, neutropenia, nausea, fatigue, rash, and peripheral neuropathy.

Note this is not a complete list of side effects for PERJETA (Pertuzumab), only common ones.